160 related articles for article (PubMed ID: 10536006)
1. The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor.
Lutterbach B; Hou Y; Durst KL; Hiebert SW
Proc Natl Acad Sci U S A; 1999 Oct; 96(22):12822-7. PubMed ID: 10536006
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.
Heibert SW; Lutterbach B; Durst K; Wang L; Linggi B; Wu S; Wood L; Amann J; King D; Hou Y
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S31-4. PubMed ID: 11587363
[TBL] [Abstract][Full Text] [Related]
3. The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain.
Durst KL; Lutterbach B; Kummalue T; Friedman AD; Hiebert SW
Mol Cell Biol; 2003 Jan; 23(2):607-19. PubMed ID: 12509458
[TBL] [Abstract][Full Text] [Related]
4. Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein.
Fenrick R; Amann JM; Lutterbach B; Wang L; Westendorf JJ; Downing JR; Hiebert SW
Mol Cell Biol; 1999 Oct; 19(10):6566-74. PubMed ID: 10490596
[TBL] [Abstract][Full Text] [Related]
5. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors.
Lutterbach B; Westendorf JJ; Linggi B; Patten A; Moniwa M; Davie JR; Huynh KD; Bardwell VJ; Lavinsky RM; Rosenfeld MG; Glass C; Seto E; Hiebert SW
Mol Cell Biol; 1998 Dec; 18(12):7176-84. PubMed ID: 9819404
[TBL] [Abstract][Full Text] [Related]
6. AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein.
Melnick A; Carlile GW; McConnell MJ; Polinger A; Hiebert SW; Licht JD
Blood; 2000 Dec; 96(12):3939-47. PubMed ID: 11090081
[TBL] [Abstract][Full Text] [Related]
7. AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia.
Meyers S; Lenny N; Sun W; Hiebert SW
Oncogene; 1996 Jul; 13(2):303-12. PubMed ID: 8710369
[TBL] [Abstract][Full Text] [Related]
8. The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation.
Meyers S; Lenny N; Hiebert SW
Mol Cell Biol; 1995 Apr; 15(4):1974-82. PubMed ID: 7891692
[TBL] [Abstract][Full Text] [Related]
9. The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation.
Westendorf JJ; Yamamoto CM; Lenny N; Downing JR; Selsted ME; Hiebert SW
Mol Cell Biol; 1998 Jan; 18(1):322-33. PubMed ID: 9418879
[TBL] [Abstract][Full Text] [Related]
10. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia.
Lutterbach B; Westendorf JJ; Linggi B; Isaac S; Seto E; Hiebert SW
J Biol Chem; 2000 Jan; 275(1):651-6. PubMed ID: 10617663
[TBL] [Abstract][Full Text] [Related]
11. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain.
Amann JM; Nip J; Strom DK; Lutterbach B; Harada H; Lenny N; Downing JR; Meyers S; Hiebert SW
Mol Cell Biol; 2001 Oct; 21(19):6470-83. PubMed ID: 11533236
[TBL] [Abstract][Full Text] [Related]
12. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex.
Wang J; Hoshino T; Redner RL; Kajigaya S; Liu JM
Proc Natl Acad Sci U S A; 1998 Sep; 95(18):10860-5. PubMed ID: 9724795
[TBL] [Abstract][Full Text] [Related]
13. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression.
Dhordain P; Lin RJ; Quief S; Lantoine D; Kerckaert JP; Evans RM; Albagli O
Nucleic Acids Res; 1998 Oct; 26(20):4645-51. PubMed ID: 9753732
[TBL] [Abstract][Full Text] [Related]
14. Functional domains of the t(8;21) fusion protein, AML-1/ETO.
Lenny N; Meyers S; Hiebert SW
Oncogene; 1995 Nov; 11(9):1761-9. PubMed ID: 7478604
[TBL] [Abstract][Full Text] [Related]
15. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
16. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription.
Hiebert SW; Sun W; Davis JN; Golub T; Shurtleff S; Buijs A; Downing JR; Grosveld G; Roussell MF; Gilliland DG; Lenny N; Meyers S
Mol Cell Biol; 1996 Apr; 16(4):1349-55. PubMed ID: 8657108
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of transcriptional repression by TEL/RUNX1 fusion protein.
Lee YJ; Kim JH; Bae S; Rho SK; Choe SY
Mol Cells; 2004 Apr; 17(2):217-22. PubMed ID: 15179033
[TBL] [Abstract][Full Text] [Related]
18. Role for the mortality factors MORF4, MRGX, and MRG15 in transcriptional repression via associations with Pf1, mSin3A, and Transducin-Like Enhancer of Split.
Yochum GS; Ayer DE
Mol Cell Biol; 2002 Nov; 22(22):7868-76. PubMed ID: 12391155
[TBL] [Abstract][Full Text] [Related]
19. The New Clinicopathologic and Molecular Findings in Myeloid Neoplasms With inv(3)(q21q26)/t(3;3)(q21;q26.2).
Wang HY; Rashidi HH
Arch Pathol Lab Med; 2016 Dec; 140(12):1404-1410. PubMed ID: 27628325
[TBL] [Abstract][Full Text] [Related]
20. Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation.
Lutterbach B; Hiebert SW
Gene; 2000 Mar; 245(2):223-35. PubMed ID: 10717473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]